Genomics World Markets
Genomics is transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics. Virtually all of the major pharmaceutical houses have either formed partnerships with genomics firms that began to emerge in the early 1990s or have created in house genomics divisions. The aim of this TriMark Publications study is to provide in depth information on the developing market for genomics products and services.
The report will include detailed market analyses and discussions of industry trends in order to assess the impact of genomics on the current and emerging pharmaceutical and diagnostic markets. Forecasts and trends were developed from interviews with industry sources, as well as from an assessment of available and emerging technologies. The report focuses on how researchers are applying new genomic approaches to drug discovery and development, and on how these technologies can be used most effectively and in a high throughput capacity. Case studies analyzing particular applications of genomic technologies to specific disease related research are provided, and future trends and developments are forecasted. Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives and others. These individuals are employed at leading genomics firms or in pharmaceutical and biotechnology companies that either contract with these firms or have developed in house genomics capabilities.
1. Introduction
1.1 Statement of Report
1.2 Objectives and Goals of Study
1.3 Methodology
1.4 Information Sources
1.5 Executive Summary
1.5.1 Market Drivers
1.5.2 Market Restraints
1.5.3 Market Size and Growth Projections
1.6 What is a Gene?
1.7 Gene Expression
1.8 Genetic Variability
1.9 Sequence Variability
1.10 Expression Variability
1.11 Opportunities Arising from Genetic Variability
1.12 The Human Genome Project (HGP)
1.13 Gene Databases
1.14 Resequencing
1.14.1 Frozen in Time
1.14.2 A Stepwise Approach
1.15 The Role of RNAi in Drug Target Validation
1.16 DNA Tags
2. Genomics Technology and Industry
2.1 The Biotechnology Industry
2.2 The Development of a Genomics Market
2.2.1 Market Size and Growth Projections
2.2.2 The U.S. Genomics Market
2.3 Biochips
2.4 Bioinformatics
2.5 Disease Targets
2.6 Functional Genomics
2.7 Gene Sequencing
2.7.1 Gene Sequence Variation Detection
2.8 Comparative Genomics
2.9 Genome Database Arrays
2.10 High-Throughput Genomics
2.11 Lab-on-a-Chip
2.11.1 Features of LabChip Systems
2.11.2 Key Benefits of LabChip Systems
2.12 High-Throughput Instrumentation
2.12.1 Automated DNA Sequencing
2.12.2 Application of High-Throughput DNA Sequencing to SAGE Analysis
2.12.3 RNA Expression Profiling Using DNA Microarrays
2.13 Pharmacogenomics
2.14 Probe Array
2.14.1 Gene Expression Monitoring Arrays
2.14.2 DNA Analysis Arrays
2.15 Proteomics
2.16 Sequencing
2.17 Single-Nucleotide Polymorphism (SNP)
2.18 Structural Genomics
2.19 Photolithography
2.20 Instrumentation
3. How Genomics Is Revolutionizing Healthcare
3.1 Pharmaceutical Applications
3.1.1 Drug Discovery and Development
3.2 Diagnostics
3.2.1 Genome Screening by Comparative Genomic Hybridization
3.2.2 MicroChip Technology and Diagnostics
3.3 Toxicogenomics
3.4 The Market for DNA Microarrays
3.5 DNA Chip Technology Competition
3.6 Expression Profiling
3.7 Gene Sequencing
3.7.1 Advantages of Chip Array Technology
3.8 Applied Markets for Genomics
3.9 Genomics and Big Pharma
3.10 The SNP Consortium
3.11 Genomics Companies and Biopharmaceutical Companies
3.12 Cancer Markets
3.13 Agricultural Markets
3.13.1 Plant Genetics
3.13.2 Food Processing
3.13.3 Animal Husbandry
4. Proprietary Applications and Patents
4.1 What is Patentable?
4.2 Patents and Litigation
5. Business Analysis
5.1 Facilitate and Capitalize on the Convergence of Gene Expression Analysis and Proteomics
5.2 Competition
5.3 Market Opportunities for Functional Genomics
5.4 The Genomics Industry is Highly Competitive
5.5 The Overview for Drug Makers
5.6 First-Generation Biotech
5.7 The Second-Generation Genomics Companies
5.8 Strategic Alliances
5.9 Genomic Business Acquisitions, Mergers and Partnering
6. Genomics Company Profiles
6.1 ACLARA BioSciences, Inc.
6.1.1 Business Strategy
6.2 Affymetrix, Inc.
6.2.1 Business Strategy
6.2.2 Gene Expression Monitoring
6.2.3 Collaborative Partners
6.2.4 Gene Expression Monitoring Collaborations
6.2.5 DNA Analysis Collaborations
6.2.6 Molecular Diagnostics Collaborations
6.2.7 Other Collaborations
6.2.8 Technology Licensees
6.3 Agilent Technologies, Inc.
6.4 Applied Biosystems Group
6.5 Bayer, AG
6.6 Clinical Micro Sensors
6.7 Celera Genomics
6.8 CuraGen Corporation
6.8.1 Business Strategy
6.8.2 Discovery
6.8.3 Preclinical
6.8.4 Clinical
6.8.5 Strategic Alliances
6.9 Diversa Corporation, Inc.
6.10 Gene Logic, Inc.
6.11 GE Healthcare
6.12 Illumina, Inc.
6.12.1 Alliances
6.12.2 Life Science Alliances
6.13 Luminex Corporation
6.13.1 Instruments
6.13.2 Consumables
6.14 Nanogen, Inc.
6.14.1 Business Overview
6.15 Orchid Biosciences, Inc.
6.15.1 Products
6.15.2 Services
6.16 Sequenom, Inc.
6.17 Research Genetics
6.18 Caliper LifeSciences
6.18.1 Business Overview
6.18.2 Corporate Strategy
6.18.3 Leading Products
6.19 Genentech, Inc./Genomic Solutions, Inc.
6.19.1 Business Overview
6.19.2 Product Information
6.19.3 Corporate Strategy
6.19.4 Leading Products
6.20 Harvard Bioscience, Inc.
6.21 Human Genome Sciences, Inc.
6.21.1 Business Overview
6.21.2 Corporate Strategy
6.21.3 Leading Products
6.22 Millennium Pharmaceuticals, Inc.
6.22.1 Business Overview
6.22.2 Leading Products
6.23 Myriad Genetics, Inc.
6.23.1 Business Overview
6.23.2 Corporate Strategy
6.23.3 Leading Product Candidates
6.24 Nanogen, Inc.
6.24.1 Business Overview
6.24.2 Leading Product Candidates
6.25 PerkinElmer, Inc.
6.25.1 Business Overview
6.25.2 Leading Products
6.26 Brief Profiles of Other Selected Genomics Firms
6.26.1 Aber Genomic Computing
6.26.2 deCODE Genetics, Inc.
6.26.3 Molecular Devices Corporation
6.26.4 Spotfire, Inc.
6.26.5 454 Life Sciences
7. Genomics Challenges and Growth Factors
7.1 Market Drivers
7.1.1 Product Pipeline: Need for More Drug Candidates
7.1.2 Need for Increased Research and Development Productivity
7.2 Genomics Market Bottlenecks
7.2.1 Cost Constraints
7.2.2 Technical Hurdles
7.3 Strategic Recommendations
7.3.1 Market Opportunities
7.4 Key Trends of Recent Mergers and Acquisition Deals
7.5 Chemogenomics
7.6 Pharmacogenomics
7.7 Biomarkers
7.8 Additional Genomics Market Opportunities
8. Bioinformatics
8.1 Types of Data and Bioinformatics Applications
8.1.1 Validated Core Modeling Technology
8.1.2 Broad Applicability
8.1.3 Data Management Compliant with Industry Standards
8.1.4 Open Architecture
8.1.5 Ease of Use
8.1.6 Increased Access
8.2 Functions of Informatics Software
8.2.1 Data Management
8.2.2 Transform Data into Knowledge
8.2.3 Collaboration Among Researchers
8.2.4 Interface for Online Data Sources
8.3 Target Markets for Informatics Software
8.3.1 Pharmaceutical Companies
8.3.2 Biotechnology Companies
8.3.3 Academic and Government Research Institutions
8.3.4 Agricultural, Environmental and Industrial Biotechnology Companies
8.4 Products of Bioinformatics
8.4.1 Sequences and Structure of Genes and Proteins
8.4.2 3-D Molecular Structures
8.4.3 Genome Structures and Functions
8.4.4 Bibliographic Data
8.5 Bioinformatics Processes
8.6 Informatics Tools and Functionalities
8.6.1 Sequence to Structure
8.6.2 Lead Identification and Optimization
8.6.3 Development and Formulation
8.6.4 Improving Materials and Processes in the Chemicals Industry
8.6.5 Other Materials-Based Industries
8.7 Role of Bioinformatics in the Value Chain
8.8 Bioinformatics Market Segments
8.8.1 Database
8.8.2 Hardware
8.8.3 Software
8.8.4 Bioinformatics Services
8.9 Bioinformatics Business Models
8.9.1 Changing Business Models
8.9.2 Selected Business Strategies
Glossary
INDEX OF FIGURES
Figure 1: Global Biotechnology Industry
Figure 2: Role of Bioinformatics in the Biotechnology Value Chain
INDEX OF TABLES
Table 1: Top U.S. Biotechnology Companies by Market Capitalization
Table 2: Top U.S. Biotechnology Companies in Genomic Segment
Table 3: Total Equity Raised by Biotech Companies by Year, 1990-2003
Table 4: Global Biotechnology Industry Major Segments 2005
Table 5: Genomics Sector Market Size, 2001?2010
Table 6: Biochip Market Size
Table 7: Selected Competitors in the Biochip Markets
Table 8: Biochip Microarray Products
Table 9: Bioinformatics Tools
Table 10: The Worldwide Market for Bioinformatics, 2000-2010
Table 11: Selected Companies Building Advanced Integrated Platforms and Genomics Databases
Table 12: Companies Using New Genomic Tools
Table 13:Detection Technology Companies for Genomics
Table 14: Spotting Technology Suppliers
Table 15: Robotics or “Lab-on-a-Chip” Market Sector
Table 16: Key High-Throughput and Systemic Approaches for Genomic Analysis
Table 17: Pharmacogenomics Segment Players
Table 18: The World Wide Market for Pharmacogenomics Through 2008
Table 19: Competitors in the SNP-Genotyping Segment
Table 20: Scanning and Detection Technology Suppliers
Table 21: Genomics Pharmaceutical Market Sector Leaders
Table 22: Companies Focused on the Genomics Biotechnology Market Sector
Table 23: Companies Focused on the Genomics Diagnostic Market Sector
Table 24: The Worldwide Market for Genomics-Based Diagnostics
Table 25: Applied Markets for Genomics
Table 26: DNA Testing Segment Players
Table 27: Opportunities for Molecular-Targeting Therapeutics for Cancer
Table 28: The Clinical Research Organizations (CRO) Sector
Table 29: Emerging Companies in the Anti-Cancer Sector
Table 30: First Generation Biotech Companies Financial Performance Market, 2003
Table 31: Biotech Companies Transitioned to Drug Companies Market, 2003
Table 32: Selected Strategic Alliances of Genomic Companies
Table 33: Commercial Organizations with Significant Sequencing Capacity
Table 34: Summary of Selected Affymetrix Expression Profiling Customers
Table 35: CuraGen’s Proprietary Technologies
Table 36: Data Source and Bioinformatic Investigations
Table 37: Bioinformatics Activities, Subactivities and Key Players
